What’s new with syngo.via?
New applications for innovative combinations
The new version of syngo.via comes with decisive benefits: it gives you access to new clinical applications for routine and advanced reading, and it helps strengthen your clinical capabilities, competitiveness, and reputation – especially regarding treatment decisions in oncology. Have a look at some of the new options:
Quantitative evaluation of functional tumor response
syngo.MR OncoCare offers a solution for quantitative evaluation of functional tumor response to treatment. That means potential for earlier assessment, enabling treatment path optimization and the saving of unnecessary costs.
Efficient and flexible viewing and contouring
syngo.via RT Image Suite provides tools for multimodality image viewing and contouring. It is designed to increases efficiency and helps get a clear and comprehensive view of the patient.
Processing and reading of studies
syngo.SPECT Processing is designed to enable reading, measuring and reporting, and measuring of SPECT/CT and SPECT studies on syngo.via. Organ-specific workflows can help improve diagnostic confidence through the quantification of nuclear medicine perfusion studies.
1syngo.via can be used as a stand-alone device or together with a variety of syngo.via-based software options, which are medical devices in their own right. syngo.via is not yet commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further information.